Peripheral neuropathy associated with leflunomide: Is there a risk patient profile?

Pharmacoepidemiology and Drug Safety

Volumn 16, Issue 1, 2007, Pages 74-78

  Martin, Karin ^a,b   Bentaberry, Fabrice ^d   Dumoulin, Chantal ^d   Miremont Salamé, Ghada ^a,b,c   Haramburu, Françoise ^a,b,c   Dehais, Joel ^d   Schaeverbeke, Thierry ^d  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b INSERM   (France)

^c Centre de Pharmacovigilance Bordeaux   (France)

^d BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

Adverse drug reaction; Leflunomide; Peripheral neuropathy

Indexed keywords

ATORVASTATIN; CHLOROQUINE; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLD SALT; LEFLUNOMIDE; METHOTREXATE; NEUROTOXIN; SALAZOSULFAPYRIDINE; TIOPRONIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; FEMALE; FOLLOW UP; FRANCE; HOSPITAL DEPARTMENT; HUMAN; INCIDENCE; MALE; MEDICAL RECORD REVIEW; NERVE CONDUCTION; NEUROLOGIC EXAMINATION; NEUROTOXICITY; PATIENT MONITORING; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK FACTOR; SEX RATIO; UNIVARIATE ANALYSIS; UNIVERSITY HOSPITAL;

EID: 33846490253     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1282     Document Type: Article

References (24)

1. Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999; 159 (21): 2542-2550.
2. Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000; 39 (6): 655-665.
3. Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999; 353 (9149): 259-266.
4. Kalden JR, Scott DL, Smolen JS, et al. Improved functional ability in patients with rheumatoid arthritis - longterm treatment with leflunomide versus sulfasalazine. European Leflunomide Study Group. J Rheumatol 2001; 28 (9): 1983-1991.
5. Cohen S, Cannon GW, Schiff M, et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of leflunomide in the treatment of rheumatoid arthritis trial investigator group. Arthritis Rheum 2001; 44 (9): 1984-1992.
6. Scott DL, Smolen JS, Kalden JR, et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 2001; 60 (10): 913-923.
7. Kalden JR, Schattenkirchner M, Sorensen H, et al. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study. Arthritis Rheum 2003; 48 (6): 1513-1520.
8. Brault I, Gossec L, Pharm T, Dougados M. Leflunomide termination rates in comparison with others DMARDs in Rheumatoid Arthritis. Arthritis Rheum 2002; 46: S540.
9. Van Pelt P, Van Schaardenburg D, Bultink I, Dijkmans B. High discontinuation rate of treatment with leflunomide in daily practice [abstract]. Arthritis Rheum 2001; 44 (suppl 9): S143.
10. Miller M, Morton G, Anderson L, Keroach B, Radis C. One year community based experience with leflunomide in the treatment of rheumatoid arthritis [abstract]. Arthritis Rheum 2000;43 (Suppl 9): S343.
11. Siva C, Eisen SA, Shepherd R, et al. Leflunomide use during the first 33 months after food and drug administration approval: experience with a national cohort of 3,325 patients. Arthritis Rheum 2003; 49 (6): 745-751.
12. Carulli MT, Davies UM. Peripheral neuropathy: an unwanted effect of leflunomide? Rheumatology (Oxford) 2002; 41 (8): 952-953.
13. Lormeau C, Vandecandelaere MNG, Schmidt J, Houvenagel E. Neuropathies périphériques au cours d'un traitement par léflunomide: deux nouvelles observations. [French]. Rev Rhum 2003; 70: 1001.
14. Martin K, Bentaberry F, Dumoulin C, et al. Neuropathy associated with leflunomide: a case series. Ann Rheum Dis 2005; 64 (4): 649-650.
15. Bharadwaj A, Haroon N. Peripheral neuropathy in patients on leflunomide. Rheumatology (Oxford) 2004; 43 (7): 934.
16. Bonnel RA, Graham DJ. Peripheral neuropathy in patients treated with leflunomide. Clin Pharmacol Ther 2004; 75 (6): 580-585.
17. Gabelle A, Antoine JC, Hillaire-Buys D, Coudeyre E, Camu W. [Leflunomide-related severe axonal neuropathy]. Rev Neurol (Paris) 2005; 161 (11): 1106-1109.
18. Moore N, Noblet C, Kreft-Jais C, Lagier G, Ollagnier M, Imbs JL. French pharmacovigilance database system: examples of utilisation. Therapie 1995; 50 (6): 557-562.
19. Martin K, Begaud B, Latry P, Miremont-Salame G, Fourrier A, Moore N. Differences between clinical trials and postmarketing use. Br J Clin Pharmacol 2004; 57 (1): 86-92.
20. Wieringa NF, de Graeff PA, van der Werf GT, Vos R. Cardiovascular drugs: discrepancies in demographics between pre- and post-registration use. Eur J Clin Pharmacol 1999; 55 (7): 537-544.
21. Wieringa NF, Vos R, van der Werf GT, van der Veen WJ, de Graeff PA. Co-morbidity of 'clinical trial' versus 'real-world' patients using cardiovascular drugs. Pharmacoepidemiol Drug Saf 2000; 9 (7): 569-579.
22. Holm EA, Balslev E, Jemec GB. Vasculitis occuring during leflunomide therapy. Dermatology 2001; 203 (3): 258-259.
23. Chan AT, Bradlow A, McNally J. Leflunomide induced vasculitis - a dose-response relationship. Rheumatology (Oxford) 2003; 42 (3): 492-493.
24. Macdonald J, Zhong T, Lazarescu A, Gan BS, Harth M. Vasculitis associated with the use of leflunomide. J Rheumatol 2004; 31 (10): 2076-2078.